{"nctId":"NCT01625000","briefTitle":"Safety and Efficacy of MP-214 in Patients With Schizophrenia","startDateStruct":{"date":"2012-05"},"conditions":["Schizophrenia"],"count":512,"armGroups":[{"label":"MP-214 3mg","type":"EXPERIMENTAL","interventionNames":["Drug: MP-214 3mg"]},{"label":"MP-214 6mg","type":"EXPERIMENTAL","interventionNames":["Drug: MP-214 6mg"]},{"label":"MP-214 9mg","type":"EXPERIMENTAL","interventionNames":["Drug: MP-214 9mg"]},{"label":"Risperidone 4mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Risperidone 4mg"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"MP-214 3mg","otherNames":[]},{"name":"MP-214 6mg","otherNames":[]},{"name":"MP-214 9mg","otherNames":[]},{"name":"Risperidone 4mg","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Written informed consent obtained from the patient before the initiation of any study-specific procedures\n* Patients diagnosed with schizophrenia according to the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia\n* Patients with normal physical examination, laboratory, vital signs, and/or electrocardiogram (ECG)\n\nExclusion Criteria:\n\n* Patients with a DSM-IV-TR diagnosis of schizoaffective disorder, schizophreniform disorder, other psychotic disorders other than schizophrenia, or bipolar I or II disorder\n\nThe information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"64 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6","description":"PANSS score is a 30-item rating scale to assess both the positive and negative symptom syndromes of patients with schizophrenia. Each item is scored on a 7-point scale, from 1 (absent) to 7 (extreme). The PANSS total score of the 30 PANSS items ranges from 30 to 210. High scores indicate greater severity of symptoms.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.4","spread":"2.0"},{"groupId":"OG001","value":"-13.8","spread":"2.0"},{"groupId":"OG002","value":"-14.0","spread":"2.9"},{"groupId":"OG003","value":"-20.2","spread":"3.0"},{"groupId":"OG004","value":"-9.5","spread":"2.1"}]}]}]},{"type":"SECONDARY","title":"Change in the Clinical Global Impression-Severity (CGI-S) Score at Week 6","description":"CGI-S is a 7-point scale to assess the global severity of the participant's illness. CGI-S scores range from 1 (normal, not ill at all) to 7 (extremely ill).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"0.1"},{"groupId":"OG001","value":"-0.8","spread":"0.1"},{"groupId":"OG002","value":"-0.7","spread":"0.2"},{"groupId":"OG003","value":"-1.2","spread":"0.2"},{"groupId":"OG004","value":"-0.6","spread":"0.1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":126},"commonTop":["Schizophrenia","Constipation","Akathisia","Extrapyramidal disorder","Headache"]}}}